Wolverine Asset Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Wolverine Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-231	Closed	-$1K	–	2543
2014 Q4	$1K	Sell	231 -100	-30%	-$853	﹤0.01%	2093
2014 Q3	$18K	Buy	+331	New	+$4.9K	﹤0.01%	1854
2014 Q2	–	Sell	-8	Closed	-$2K	–	2802
2014 Q1	$2K	Hold	8	–	–	﹤0.01%	2205
2013 Q4	$3K	Buy	+8	New	+$151	﹤0.01%	2493
2013 Q3	–	Sell	-100	Closed	-$17K	–	3113
2013 Q2	$17K	Buy	+100	New	+$1.77K	﹤0.01%	2084

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wolverine Asset Management's RPRX Position: Q1 2015 in Review

Wolverine Asset Management sold out of Repros Therapeutics Inc. (RPRX) in Q1 2015, closing a stake of 5,100 shares — an estimated $50K sold.

Wolverine Asset Management first reported a position in RPRX in Q2 2013 and held it in 6 quarters. The position peaked at $250K in Q2 2013. 72 funds tracked by Wall St. Rank hold RPRX as of Q1 2015.

Wolverine Asset Management reported no remaining Repros Therapeutics Inc. position as of Q1 2015 after selling out during the quarter.
Wolverine Asset Management sold 5,100 Repros Therapeutics Inc. shares in Q1 2015, an estimated $50K.
Wolverine Asset Management first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 6 quarters.
Wolverine Asset Management's Repros Therapeutics Inc. position peaked at $250K in Q2 2013.
72 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2015.

Based on Wolverine Asset Management's 13F filing for Q1 2015, filed 15 May 2015.